标题: [讨论]GWD-8-Q5 [打印本页]
作者: wenbowei911 时间: 2011-2-23 06:48 标题: [讨论]GWD-8-Q5
我看大家都没有问这个问题 Frazier and Mosteller assert that
medical research could be improved by
a move toward larger, simpler clinical
Line
trials of medical treatments. Currently,
(5)
researchers collect far more background
information on patients than is strictly
required for their trials—substantially more
than hospitals collect—thereby escalating
costs of data collection, storage, and
(10)
analysis. Although limiting information
collection could increase the risk that
researchers will overlook facts relevant
to a study, Frazier and Mosteller contend
that such risk, never entirely eliminable
(15)
from research, would still be small in most
studies. Only in research on entirely new
treatments are new and unexpected variables
likely to arise.
Frazier and Mosteller propose not
(20)
only that researchers limit data collection
on individual patients but also that
researchers enroll more patients in clinical
trials, thereby obtaining a more representative
sample of the total population with
(25)
the disease under study. Often researchers
restrict study participation to patients
who have no ailments besides those being
studied. A treatment judged successful
under these ideal conditions can then
(30)
be evaluated under normal conditions.
Broadening the range of trial participants,
Frazier and Mosteller suggest, would
enable researchers to evaluate a treatment’s
efficacy for diverse patients under
(35)
various conditions and to evaluate its
effectiveness for different patient subgroups.
For example, the value of a
treatment for a progressive disease may
vary according to a patient’s stage of
(40)
disease. Patients’ ages may also affect
a treatment’s efficacy.
GWD-8-Q5 :
The author mentions patients’ ages(line 40) primarily in order to
A identify the most critical variable differentiating subgroups of patients
B cast doubt on the advisability of implementing Frazier and Mosteller’s proposals about medical research
C indicate why progressive diseases may require different treatments at different stages
D illustrate a point about the value of enrolling a wide range of patients in clinical trials
E substantiate an argument about the problems inherent in enrolling large numbers of patients in clinical trials
--------------------------------------------------------------------------------
answer: D
我现在也认同D是没有问题得,但是为什么C不对那,难道C只是例子里面得一个小的方面,而D中说的范围更大?
谢谢
作者: victoria820 时间: 2011-2-23 20:31
lz再读一下最后几句,a patient’s stage of disease与Patients’ ages是两码事
作者: angelsgx 时间: 2011-2-24 06:44
整篇文章的意思 大概是說明一個新的治療方式
它的優點,和實際實施下所遇到的不足和有風險的方面,
從line 19)之後到文章結束,此段更能得知這個治療方式需要應用在更多不同的病患上,
以至於才能夠認定這個treatment的可靠性和可行性! 文章內容大意 以上.
你說 C) indicate why progressive diseases may require different treatments at different stages
其核心句意為"progressive diseases" 在不同的階段需要不同的治療方式
然而再回顧整篇文章,並沒有傳達和提及關於diseases嚴重程度的治療方式.
作者: wenbowei911 时间: 2011-2-24 21:53
多谢
作者: ddwantsmba 时间: 2011-2-25 21:06
定位在第二段第一句话的后半句
but also that researchers enroll more patients in clinical trials, thereby obtaining a more representative sample of the total population with the disease under study.
正是因为patients' agesa会影响到疗效,所以才应该enroll more patients in clinical trials。
欢迎光临 国际顶尖MBA申请交流平台--TOPWAY MBA (http://forum.topway.org/) |
Powered by Discuz! 7.2 |